CClinicalTrials.gg
Not yet recruitingNCT07613281Updated Jun 1, 2026

Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).

An interventional study of Palatal Implant System in Snoring and OSA - Obstructive Sleep Apnea, sponsored by Serene Sleep, Inc.. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Serene Sleep, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical investigation is a prospective, non-randomized, parallel-group clinical investigation conducted at two (2) investigative sites. Study participants will be assigned to one of two study groups, snoring and obstructive sleep apnea, in a parallel manner based on predefined eligibility criteria.

The study aims to evaluate and compare outcomes between the two groups under investigation. The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.

The design allows for the concurrent enrollment and follow-up of participants in both arms, enabling direct observation of differences in safety across the groups over time.

02

Conditions studied

  • Snoring
  • OSA - Obstructive Sleep Apnea

Keywords

  • Snoring
  • Obstructive Sleep Apnea
  • Sleep Apnea
  • Hypopnea
  • Sleep-Disordered Breathing
  • Sleep Implant
  • Airway Support Implant
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

A potential participant must meet ALL the following criteria to be enrolled into this study:

  1. Participant is ≥18 years of age.
  2. Participant has Body Mass Index (BMI) less than or equal to 30 kg/m²
  3. Participant has a tonsil grade less than or equal to 2
  4. Participant has a Friedman Tongue Position (FTP) I or II
  5. Participant is able to provide voluntary written informed consent.

For a snoring participant to be selected for the study:

  • Confirmed identification of palatal snoring

    • Investigators will utilize standard of care clinical assessment methods to confirm the presence of palatal snoring prior to enrollment. These methods may include patient-reported history, physical examination of the upper airway, and auscultation or audio recordings.
  • Confirmed elimination of potential sleep apnea diagnosis

    • If the evaluating doctor suspects that the participant may be experiencing OSA, investigators will utilize standard of care clinical assessment methods to confirm OSA.
    • A resulting AHI \<5 would classify the participant as an eligible snoring subject

For an OSA participant to be selected for study:

Confirmed identification of apnea caused by palatal collapse

  • Investigators should be able to make this identification through intraoral evaluation in accordance with their standard of care
  • Confirmed mild-to-moderate classification of OSA

    • If the evaluating investigator knows or suspects that the participant may be experiencing OSA, standard of care diagnostic methods will be used as confirmation.
    • A resulting AHI between 5 and 30 would classify the participant as an eligible OSA subject.

Exclusion criteria

EXCLUSION CRITERIA

A potential participant will be excluded from enrollment if ANY of the following conditions apply:

  1. A record of allergic reaction to polyethylene terephthalate (PET) / polyester
  2. An overly sensitive gag reflex
  3. Septal deviation or nasal obstruction
  4. Nasal polyps
  5. Severe seasonal allergies
  6. Soft palate length insufficient to accommodate implants
  7. Prior Diagnosis of Lingual tonsil hypertrophy
  8. Hypopharyngeal obstruction
  9. Previous pharyngeal surgery
  10. Previous upper respiratory tract cancer or radiation therapy
  11. Active respiratory tract infection
  12. Dysphagia or speech disorder
  13. Neurologic disorder
  14. Unstable psychiatric disorder
  15. Pregnant or breastfeeding
  16. History of falling asleep driving or Motor Vehicle Accident (MVA) due to sleepiness
  17. Clinical Presentation that suggests Severe OSAHS (ESS >20, participant report of choking or gasping during sleep, etc.)
  18. Marfan's Syndrome, Ehler-Danlos syndromes or other disorders of connective tissue and/or muscular tissue
  19. Other sleep disorders
  20. Other significant craniofacial anomaly
  21. Participant is participating in any of the following:

    • A study with the same or similar primary endpoint
    • Any study in which the investigator determines may interfere with the results of this study
  22. Participant is unwilling to complete all study related assessments and follow-up visits
  23. Participant is unwilling or unable to abstain from all alcohol consumption for 24 hours leading up to the intake sleep study
  24. Participant is unwilling or unable to abstain from all smoking, vaping, and/or oral tobacco products for 48 hours following the procedure
  25. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Snoring Group

    Implant with the Serene Sleep Palatal Implant System

    Device: Palatal Implant System

  • Experimental
    Mild to Moderate OSA Group

    Implant with the Serene Sleep Palatal Implant System

    Device: Palatal Implant System

Interventions

  • DevicePalatal Implant System

    Serene Sleep Palatal Implant System

05

What researchers measure

Primary outcomes

  1. Proportion of Participants with Implant Extrusion at 30 Days and Absence of Serious Adverse Device Effects (SADEs) [Hybrid Composite Safety Endpoint]

    The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.

    Time frame: From baseline to 30 days post-procedure

Secondary outcomes

  1. Change is Visual Analogue Scale (VAS) Score

    The change in subjective snoring severity as measured by a 10 cm Visual Analogue Scale (VAS), scored 0-10, where 0 = no snoring and 10 = extremely annoying snoring (higher scores indicate worse outcome).

    Time frame: From baseline to 30 days post-procedure

  2. Change in Snoring Outcomes Survey (SOS)

    The change in subjective snoring as measured by the Snoring Outcomes Survey (SOS), an 8-item validated instrument assessing intensity, duration, frequency, and impact of snoring/sleep-disordered breathing symptoms.

    Time frame: From baseline to 30 days post-procedure

Other outcomes

  1. Change in daytime Epworth Sleepiness Scale (ESS)

    The change in daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), a validated 8-item questionnaire scored 0-24, where 0 = no daytime sleepiness and 24 = severe daytime sleepiness (higher scores indicate worse outcome).

    Time frame: From baseline to 30 days post-procedure

  2. Change in Apnea-Hypopnea Index (bAHI3) via Home Sleep Apnea Test

    AHI Score calculated using a 3% oxygen desaturation threshold (bAHI3), collected via the Belun Sleep System HSAT device. Data will be anonymized; complete reports will be utilized as exploratory data.

    Time frame: From baseline to 30 days post-procedure

  3. Change in Apnea-Hypopnea Index (bAHI4) via Home Sleep Apnea Test

    AHI Score calculated using a 4% oxygen desaturation threshold (bAHI4), collected via the Belun Sleep System HSAT device.

    Time frame: From baseline to 30 days post-procedure

  4. Change in Minimum Oxygen Saturation (SpO₂) via Home Sleep Apnea Test

    Minimum SpO₂ recorded during the sleep study period, collected via the Belun Sleep System HSAT device.

    Time frame: From baseline to 30 days post-procedure

  5. Change in Time with Oxygen Saturation ≤90% via Home Sleep Apnea Test

    Total cumulative duration during which SpO₂ was recorded at or below 90%, collected via the Belun Sleep System HSAT device.

    Time frame: From baseline to 30 days post-procedure

  6. Change in Sleep Efficiency via Home Sleep Apnea Test

    Sleep efficiency calculated as the proportion of time in bed spent asleep, collected via the Belun Sleep System HSAT device.

    Time frame: From baseline to 30 days post-procedure

  7. Change in Total Sleep Time (TST) via Home Sleep Apnea Test

    Total duration of sleep recorded during the study period, collected via the Belun Sleep System HSAT device.

    Time frame: From baseline to 30 days post-procedure

  8. Change in Mean Pulse Rate via Home Sleep Apnea Test

    Mean pulse rate recorded during the sleep study period, collected via the Belun Sleep System HSAT device.

    Time frame: From baseline to 30 days post-procedure

  9. Change in Arrhythmia Ratio via Home Sleep Apnea Test

    Ratio of arrhythmic heartbeats to total heartbeats recorded during the sleep study period, collected via the Belun Sleep System HSAT device

    Time frame: From baseline to 30 days post-procedure

  10. Change in Auditory Evaluation of Snoring

    Outcome 6a: "Change in Objective Snoring Volume (decibels) via Audio Recording" - the change in mean snoring volume (dB) captured by at-home overnight audio recording. Outcome 6b: "Change in Objective Snoring Frequency (Hz) via Audio Recording" - the change in dominant snoring frequency captured by at-home overnight audio recording.

    Time frame: From baseline to 30 days post-procedure

  11. Proportion of Participants with Implant Migration or Trend Toward Extrusion as Assessed by Oropharyngeal Examination at 30 Days

    At each post-procedure visit (Day 7 and Day 30), the physician will conduct a standardized oropharyngeal examination to evaluate and document whether implant location has changed from the original placement position or is trending toward extrusion. Findings will be recorded as a binary outcome (yes/no change in location) and summarized descriptively.

    Time frame: Date of procedure to 30 days post-implant

06

Study locations

2 sites
  • Aesthetic Surgery Center
    San Francisco, California 94102, United States
  • Augusta ENT
    Evans, Georgia 30907, United States
    • Jonathan P Lindman, MD · Contact · lindmanresearch@gmail.com · 706-868-5676
    • Jonathan P Lindman, MD · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07613281
Lead sponsor
Serene Sleep, Inc.
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

Chief Technology Officer
Contact
kelsey@serenesleep.com
415-707-1107

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion